Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Thrombosis and Haemostasis

• Publication date

  2013-05-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1160/TH12-12-0907PMID 23636219
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism].

  2013cited by this paper
• Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model

  2012cited by this paper
• Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

  2012cited by this paper
• Evaluation of Prothrombin Complex Concentrate and Recombinant Activated Factor VII to Reverse Rivaroxaban in a Rabbit Model

  2012influential reference
• Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban

  2012cited by this paper
• Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.

  2011cited by this paper
• Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects

  2011cited by this paper
• Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents

  2011influential reference
• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

  2011cited by this paper
• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

  2011cited by this paper
• Oral rivaroxaban for symptomatic venous thromboembolism.

  2011cited by this paper
• Erratum to: Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention

  2011cited by this paper
• Rivaroxaban: A New Oral Factor Xa Inhibitor

  2010cited by this paper
• The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleedings in patients with haemophilia A with an inhibitor to Factor VIII

  2010cited by this paper
• Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty

  2010cited by this paper
• Oral rivaroxaban for symptomatic venous thromboembolism.

  2010cited by this paper
• Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• Warfarin-reversal: results of a phase III study with pasteurised, nanofiltrated prothrombin complex concentrate.

  2008influential reference
• Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate

  2008cited by this paper
• Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents.

  2008cited by this paper
• Recombinant human factor VIIa and a factor VIIa‐analogue reduces heparin and low molecular weight heparin (LMWH)‐induced bleeding in rats

  2008cited by this paper
• Hemostatic effect of activated factor VII without promotion of thrombus growth in melagatran-anticoagulated primates.

  2007influential reference
• Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation.

  2007cited by this paper
• Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases

  2007cited by this paper
• Characterization of recombinant murine factor VIIa and recombinant murine tissue factor: a human-murine species compatibility study.

  2005cited by this paper
• Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects

  2005cited by this paper
• In vitro and in vivo studies of the novel antithrombotic agent BAY 59‐7939—an oral, direct Factor Xa inhibitor

  2005cited by this paper
• Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59‐7939, an oral, direct factor Xa inhibitor

  2005cited by this paper
• FEIBA®: mode of action

  2004cited by this paper
• Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  2004cited by this paper
• Assessment of recombinant factor VIIa as an antidote for bleeding induced in the rabbit by low molecular weight heparin

  2003cited by this paper
• Ability of Recombinant Factor VIIa to Reverse the Anticoagulant Effect of the Pentasaccharide Fondaparinux in Healthy Volunteers

  2002cited by this paper
• A Cell-based Model of Hemostasis

  2001cited by this paper
• Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.

  2001cited by this paper
• Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits.

  2001cited by this paper
• Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency

  1999cited by this paper
• Enoxaparin suppresses thrombin formation and activity during cardiopulmonary bypass in baboons.

  1998cited by this paper
• r-Hirudin inhibits platelet-dependent thrombosis during cardiopulmonary bypass in baboons.

  1998cited by this paper
• Prospective, Randomised Trial of Two Doses of rFVIIa (NovoSeven) in Haemophilia Patients with Inhibitors Undergoing Surgery

  1998cited by this paper
• Multicenter Retrospective Study on the Utilization of FEIBA in France in Patients with Factor VIII and Factor IX Inhibitors

  1997cited by this paper
• A Critical Reappraisal of the Bleeding Time*

  1990cited by this paper
• The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial.

  1981cited by this paper
• Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial.

  1980cited by this paper
• Bleeding time in laboratory animals. II - A comparison of different assay conditions in rats.

  1979cited by this paper
• Blood‐Clotting Mechanisms of Nonhuman Primates

  1972cited by this paper

• Reversal agents for current and forthcoming direct oral anticoagulants.

  2023cites this paper
• Recommendations for the use of andexanet alfa in the management of bleeding in patients on oral factor Xa inhibitors in Switzerland.

  2023cites this paper
• Comparative analysis of andexanet alfa and prothrombin complex concentrate in reversing anticoagulation by rivaroxaban ex vivo.

  2023cites this paper
• A Historical Perspective on the Reversal of Anticoagulants.

  2022cites this paper
• Real‐world decision‐making in the management of patients presenting with major bleeding on rivaroxaban: the Auckland regional experience

  2022cites this paper
• Direct Oral Anticoagulant Reversal for Management of Bleeding and Emergent Surgery

  2021cites this paper
• Efficacy of prothrombin complex concentrate in the management of oral factor Xa inhibitors associated major bleed assessed by ISTH and ANNEXA-4 criteria

  2021cites this paper
• Reversing Rivaroxaban Anticoagulation as Part of a Multimodal Hemostatic Intervention in a Polytrauma Animal Model

  2021cites this paper
• Evaluation of anticoagulation re-initiation practices following reversal of factor Xa inhibitors with andexanet alfa or 4F-PCC in patients with major bleeding events

  2021cites this paper
• High-dose versus low-dose 4-factor prothrombin complex concentrate for factor Xa inhibitor reversal in intracranial hemorrhage.

  2021cites this paper
• Anticoagulation reversal for intracranial hemorrhage in the era of the direct oral anticoagulants.

  2020cites this paper
• Adjunct Factor Replacement

  2020cites this paper
• Reversal Agents for the Direct Factor Xa Inhibitors: Biochemical Mechanisms of Current and Newly Emerging Therapies

  2020cites this paper
• Activated prothrombin complex concentrates for direct oral anticoagulant-associated bleeding or urgent surgery: Hemostatic and thrombotic outcomes.

  2020cites this paper
• Assessing and Reversing the Effect of Direct Oral Anticoagulants on Coagulation

  2020cites this paper
• Administration of high-dose four-factor prothrombin complex concentrate for Xa inhibitor reversal to prevent expansion of intracranial hemorrhage with computed tomography angiography spot sign: a case report

  2020cites this paper
• Hematologic Interventions for Acute Central Nervous System Disease

  2019cites this paper
• Four-factor Prothrombin Complex Concentrate for the Management of Patients Receiving Direct Oral Activated Factor X Inhibitors.

  2019cites this paper
• Four-factor prothrombin complex concentrate for the reversal of factor Xa inhibitors for traumatic intracranial hemorrhage.

  2019cites this paper
• Étude des facteurs expliquant la survenue d'un événement hémorragique chez des patients âgés sous anticoagulants (AVK ou AOD)

  2019cites this paper
• Reversal Agents: What We Have and What We Can Expect

  2018cites this paper
• Blutungen unter direkten oralen Antikoagulanzien

  2018cites this paper
• Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors

  2018cites this paper
• How can we reverse bleeding in patients on direct oral anticoagulants?

  2018cites this paper
• How I manage patients with anticoagulation-associated bleeding or urgent surgery.

  2018cites this paper
• Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding

  2018cites this paper
• Pharmacologic Reversal Agents

  2018cites this paper
• Pharmacological reversal of the direct oral anticoagulants—A comprehensive review of the literature

  2018cites this paper
• The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review

  2018cites this paper
• Hemostatic profile under fluid resuscitation during rivaroxaban anticoagulation: an in vitro survey

  2018cites this paper
• Rivaroxaban-Associated Intraparenchymal Hemorrhage Managed with 4-Factor Prothrombin Complex Concentrate

  2018cites this paper
• The Changing Landscape of Trauma Care, Part 1

  2017cites this paper
• Reversal Agents for Oral Antiplatelet and Anticoagulant Treatment During Bleeding Events: Current Strategies.

  2017cites this paper
• The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban‐treated patients in vitro

  2017cites this paper
• Initial anticoagulation in patients with pulmonary embolism: thrombolysis, unfractionated heparin, LMWH, fondaparinux, or DOACs?

  2017cites this paper
• Acquired Bleeding Disorders.

  2017cites this paper
• Management of neurologic complications of coagulopathies.

  2017cites this paper
• Use of direct oral anticoagulants for treatment of atrial fibrillation in patients with HIV: a review

  2017cites this paper
• The Reversal of Direct Oral Anticoagulants in Animal Models

  2017cites this paper
• Reversal of Direct Oral Anticoagulants: Current Status and Future Directions

  2017cites this paper
• The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor

  2017cites this paper
• Anticoagulant Reversal and Anesthetic Considerations.

  2017cites this paper
• Idarucizumab for Reversal of Dabigatran-Associated Bleeding: Misnomer or Miracle?

  2017cites this paper
• How we treat bleeding associated with direct oral anticoagulants.

  2016cites this paper
• Editors’ Choice 2015 papers in Thrombosis and Haemostasis

  2016cites this paper
• Reversal Agents for the Direct Oral Anticoagulants.

  2016cites this paper
• Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.

  2016cites this paper
• Diagnosis and Management of Coagulopathy-Related Intracerebral Hemorrhage

  2016cites this paper
• Animal Models of Thrombosis From Zebrafish to Nonhuman Primates: Use in the Elucidation of New Pathologic Pathways and the Development of Antithrombotic Drugs.

  2016cites this paper
• Periprocedural management of anticoagulation in patients taking novel oral anticoagulants: Review of the literature and recommendations for specific populations and procedures.

  2016cites this paper
• Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay

  2016cites this paper
• Managing Subdural Bleeding Associated With Rivaroxaban

  2016cites this paper
• A Review on the Reversal of the Old and New Anticoagulants

  2016influential citation
• Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation

  2016cites this paper
• Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage

  2016cites this paper
• Who, when, and how to reverse non-vitamin K oral anticoagulants

  2016cites this paper
• In vitro reversal of supratherapeutic rivaroxaban levels with coagulation factor concentrates.

  2016cites this paper
• Management of Periprocedural and Early Pericardial Effusions With Tamponade Following Ablation of Atrial Fibrillation With Uninterrupted Factor Xa Inhibitors: A Case Series

  2016cites this paper
• A rapid pro-hemostatic approach to overcome direct oral anticoagulants

  2016cites this paper
• Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment

  2016cites this paper
• Prothrombin Complex Concentrate, a General Antidote for Oral Anticoagulation

  2016cites this paper
• DIRECT ORAL ANTICOAGULANTS

  2016cites this paper
• Classes of Drugs and Blood Products for Acute Reversal of Anticoagulant Effect

  2016cites this paper
• UvA-DARE ( Digital Academic Repository ) Diagnosis , treatment and long-term effects of venous thromboembolism

  2016cites this paper
• Considerations for Coagulation in the Multi‐trauma Patient

  2016cites this paper
• UvA-DARE ( Digital Academic Repository ) Diagnosis , treatment and long-term effects of venous thromboembolism

  2016cites this paper
• In vivo reversal of the anticoagulant effect of rivaroxaban with four‐factor prothrombin complex concentrate

  2016influential citation
• Reversing the Effect of Oral Anticoagulant Drugs: Established and Newer Options

  2016cites this paper
• Management of Bleeding With Non–Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents

  2016cites this paper
• Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents

  2015influential citation
• Problem-Based Review: Non Vitamin K Antagonist Oral Anticoagulants for the Acute Physician.

  2015cites this paper
• Monitoring and reversal strategies for new oral anticoagulants

  2015cites this paper
• New Oral Anticoagulants and Their Reversal.

  2015cites this paper
• Reversal of rivaroxaban-induced alterations on hemostasis by different coagulation factor concentrates – in vitro studies with steady and circulating human blood.

  2015cites this paper
• In vivo increase in thrombin generation by four‐factor prothrombin complex concentrate in apixaban‐treated healthy volunteers

  2015cites this paper
• Monitoring the Effects and Antidotes of the Non-vitamin K Oral Anticoagulants.

  2015cites this paper
• Reversal Strategies for Intracranial Hemorrhages in Patients Taking Oral Factor Xa Inhibitors

  2015cites this paper
• Reversal of rivaroxaban anticoagulation by nonactivated prothrombin complex concentrate in urgent surgery.

  2015cites this paper
• Novel oral anticoagulants: efficacy, laboratory measurement, and approaches to emergent reversal.

  2015cites this paper
• Cardiovascular Therapeutics Reversal Strategies for Intracranial Hemorrhages in Patients Taking Oral Factor Xa Inhibitors

  2015cites this paper
• A new mechanism-driven bypassing strategy for direct factor Xa inhibitors reveals an unexpected property of target specific anticoagulants

  2015influential citation
• Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants

  2015cites this paper
• Qué hacer ante una complicación hemorrágica en pacientes tratados con nuevos anticoagulantes orales

  2015cites this paper
• Global assays and the management of oral anticoagulation

  2015cites this paper
• Editors' Choice papers in Thrombosis and Haemostasis.

  2015cites this paper
• Multimodal assessment of non‐specific hemostatic agents for apixaban reversal

  2015cites this paper
• Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation

  2015cites this paper
• Antidotes for novel oral anticoagulants: current status and future potential.

  2015cites this paper
• Management of Bleeding Associated with New Oral Anticoagulants

  2015cites this paper
• Pretreatment with rivaroxaban attenuates stroke severity in rats by a dual antithrombotic and anti-inflammatory mechanism

  2015cites this paper
• Editors’ Choice papers in Thrombosis and Haemostasis

  2015cites this paper
• Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants

  2015cites this paper
• Towards the development of specific antidotes: Idarucizumab for reversal of dabigatran effects

  2015cites this paper
• Reversal of Dabigatran-induced Bleeding by Coagulation Factor Concentrates in a Rat-tail Bleeding Model and Lack of Effect on Assays of Coagulation

  2014cites this paper
• Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence

  2014cites this paper
• Management of hemorrhagic complications associated with antithrombotic therapy

  2014cites this paper
• O Concentrado de Complexo Protrombínico e suas aplicações na sala de cirurgia

  2014cites this paper
• Rivaroxaban for stroke prevention in atrial fibrillation Rivaroxaban : a once-daily oral anticoagulant

  2014cites this paper
• The role of prothrombin complex concentrates in reversal of target specific anticoagulants

  2014influential citation
• Management of the Bleeding Patient Receiving New Oral Anticoagulants: A Role for Prothrombin Complex Concentrates

  2014cites this paper